<DOC>
	<DOC>NCT01216995</DOC>
	<brief_summary>Double blind, prospective, randomized, placebo-controlled Safety and Efficacy trial of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction (STEMI).</brief_summary>
	<brief_title>Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)</brief_title>
	<detailed_description>This is a prospective, randomized, two arm, placebo-controlled, double blind, study that will enroll approximately 216 patients at no more than thirty-five (35) international clinical sites. Additional blinding measures will be taken in the assessment of study outcomes. The dose of the test material (ADRCs)is described in the protocol. The study will include two arms.</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Key STsegment Elevation Myocardial Infarction (STEMI) Criteria: Ischemic symptoms AND ECG: Development of pathologic Q waves on the ECG; or ECG changes indicative of severe ischemia (ST segment elevation and/or depression); or New left bundle branch block; AND Creatine Phosphokinase Isoenzyme (MB Form) &gt; 100 IU/L, or troponin &gt;5x the upper limit of normal between admission and randomization Successful revascularization of the culprit lesion in a major epicardial vessel Key More than 24 hours between PCI and start of liposuction Prior myocardial infarction, cardiomyopathy, or a history of congestive heart failure Pacemaker, ICD, or any other contraindication for MRI Patients with increased bleeding risk Cardiogenic shock present postindex PCI</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Heart Attack</keyword>
	<keyword>Regenerative Cells</keyword>
	<keyword>Stem Cells</keyword>
</DOC>